

of ENOVID have also been reported (erythema multiforme and nodosum, hemorrhagic eruption, lupus erythematosus and acne).

Breast changes similar to those encountered in early pregnancy may be manifested. Patients receiving ENOVID for appreciable periods of time may occasionally exhibit weight gain. It is not determined whether this represents an anabolic effect or is merely the result of a psychologic effect such as freedom from the fear of pregnancy.

Loss of scalp hair or excessive growth of body hair has been reported occasionally. It is not yet clear as to the exact relationship of ENOVID administration to this manifestation (which is

seen only rarely) but from studies now in progress it appears that such changes when they occur are more closely identified with similar changes in hair growth pattern seen during pregnancy and in the postpartum period than with other possible mechanisms.

Headache, dizziness, diarrhea and abdominal pain have been reported occasionally.

How Supplied

ENOVID-E

2.5-mg. (debossed E on one side and debossed SEARLE on the other side), uncoated, unscored, pale pink tablets containing 2.5 mg. of norethynodrel

and 0.1 mg. mestranol; boxes of 120 and 600 (6 and 30 Calendar-Packs™ of 20 tablets each), and bottles of 250.

ENOVID

5-mg. (debossed 5 on one side and debossed SEARLE on the other side), unscored, uncoated, light pink tablets containing 5 mg. of norethynodrel and 0.075 mg. of mestranol; boxes of 120 and 600 (6 and 30 Calendar-Packs™ of 20 tablets each), and bottles of 100 and 500.

10-mg. (debossed 10 on one side and debossed SEARLE on the other side), unscored, uncoated, coral-colored tablets containing 9.85 mg. of norethynodrel and 0.15 mg. of mestranol; bottles of 50 and 500.